Prostate Cancer
Fifteen-Year Outcomes of the ProtecT Trial for Localized Prostate Cancer.
September 25, 2023
Germline DNA Repair Genes Pathogenic Variants Among Mexican Patients With Prostate Cancer.
September 25, 2023
Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses.
September 25, 2023
A polygenic two-hit hypothesis for prostate cancer.
September 25, 2023
A Transgender Patient with Prostate Cancer: Lessons Learnt.
September 25, 2023
Aggressive Prostate Cancer Is Preventable and so Are Racial Disparities.
September 25, 2023
Suppression of tumor cell lactate-generating signaling pathways eradicates murine PTEN/p53-deficient aggressive-variant prostate cancer via macrophage phagocytosis.
September 25, 2023
Evaluation of CD47 in the Suppressive Tumor Microenvironment and Immunotherapy in Prostate Cancer.
September 25, 2023
Barriers to and facilitators of prostate cancer screening among men in Uganda prisons.
September 25, 2023
Risk Modeling for Individualization of the FLAME Focal Boost Approach in External Beam Radiation Therapy for Patients With Localized Prostate Cancer.
September 22, 2023
PI-RADS Version 2.0 Versus Version 2.1: Comparison of Prostate Cancer Gleason Grade Upgrade and Downgrade Rates From MRI-Targeted Biopsy to Radical Prostatectomy.
September 22, 2023
Local Therapy on Clinically Lymph Node-positive Prostate Cancer: A Systematic Review and Meta-analysis.
September 22, 2023
Delta radiomic patterns on serial bi-parametric MRI are associated with pathologic upgrading in prostate cancer patients on active surveillance: preliminary findings.
September 22, 2023
mpMRI-targeted biopsy of the prostate in men ≥ 75 years. 7-year report from a high-volume referral center.
September 22, 2023